GJA5 and depressive disorder: Experimental data from animal studies supported the idea that the Sigma-1 receptor agonist (SA4503) might be the promising pharmacological agent to treat depression-related AF by increasing conduction function, improving the expression of connexin 40 and 43, and reducing cardiac myocardial inflammation, but it has not been used in clinical practice (50, 51).